CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating

Negative
AI Analysis

Summary

Chardan Research reduced ProQR Therapeutics' price target from $4 to $3 while maintaining a Buy rating on the stock.

Importance:2/10
Sentiment:
-0.30
price_target_reductionanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on June 26, 2026 12:17 PM

Read Original